Intervention of irbesartan combining rosuvastatin to vascular remodeling in mice with vascular injury
LIU Ying-jie
LIU Shao-kui
GAO Xin-yu
Abstract：Objective To observe the influence of irbesartan combining rosuvastatin on vascular remodeling in mice with vascular injury. Methods Male C57BL/6 wild mice (n=50, 8 weeks old) were randomly divided into sham-operation group, operation group, irbesartan group (50 mg/kg·d), rosuvastatin group (5 mg/kg·d), irbesartan (0.5 mg/kg·d)+rosuvastatin (2 mg/kg·d) group (each n=10). The model of femoral artery injury was established by using cannula. After 14-day intragastrical medication, the mice were executed and femoral samples were collected. The intima area was measured by using HE staining and NIH image analysis software, and expressions of MCP-1 mRNA, CCR2 mRNA and PPARγmRNA were detected by using RT-PCR. The indexes of blood fat and liver function were detected in all groups before and after treatment. Results There was no intima hyperplasia in sham-operation group (0μm2). There were neointima formation in operation group (6497±5.7)μm2, irbesartan group (5979±1.4)μm2, rosuvastatin group (6005±5.8)μm2 and irbesartan+rosuvastatin group (2269±2.8)μm2 compared with sham-operation group (all P<0.05). The difference in intima hyperplasia area had no statistical significance between operation group and irbesartan group or rosuvastatin group (all P>0.05). The intima hyperplasia area decreased in irbesartan+rosuvastatin group compared with operation group, irbesartan group and rosuvastatin group (all P<0.05). The expression of MCP-1 mRNA increased in operation group, irbesartan group, rosuvastatin group and irbesartan+rosuvastatin group compared with sham-operation group (all P<0.05), and decreased in irbesartan+rosuvastatin group compared with operation group, irbesartan group and rosuvastatin group (all P<0.05). The expression of CCR2 mRNA increased in operation group, irbesartan group, rosuvastatin group and irbesartan+rosuvastatin group compared with sham-operation group (all P<0.05). The expression of PPARγmRNA decreased in operation group, irbesartan group, rosuvastatin group and irbesartan+rosuvastatin group compared with sham-operation group (all P<0.05), and increased in irbesartan+rosuvastatin group compared with operation group, irbesartan group and rosuvastatin group (all P<0.05). The expression of MCP-1 mRNA was negatively correlated to the expression of PPARγmRNA (r=-0.607, P<0.05). Conclusion Irbesartan combining rosuvastatin can reduce the expression of MCP-1 mRNA and delay remodeling of injured vessel through increase the expression of PPARγmRNA.
Keywords：Inflammatory signal pathwayVascular remodelingMonocyte chemoattractant protein-1Peroxisome proliferator-activated receptor-γVascular injurymice
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 72-76 )